Tharimmune, Inc. issued a comprehensive corporate update on August 4, 2025, highlighting significant advancements across its pipeline and financial activities. The company reported closing approximately $5.47 million in equity financing during the second and third quarters of 2025.
The update underscored the rapid progression of TH104 as a lead asset, addressing critical national security risks posed by weaponized fentanyl. TH104 is positioned as a critical national security solution.
Additionally, the company emphasized the transformative potential of TH023 in pioneering oral antibody delivery for widespread inflammatory conditions. The update also noted strengthening operational leadership, corporate governance, and accounting functions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.